Concepedia

Publication | Open Access

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

DOIFull Paper Access

67

Citations

45

References

2015

Year

Naval Daver, Yanis Boumber, Hagop M. Kantarjian, Farhad Ravandi, Jörge E. Cortes, Michael Rytting, Jitesh D. Kawedia, Jordan Basnett, Kirk S. Culotta, Zhihong Zeng,
Clinical Cancer Research

Abstract

The combination of HyperCVAD and everolimus is well tolerated and moderately effective in relapsed ALL, specifically T-ALL.

References

YearCitations

Page 1